27 results on '"Fernandez, Hugo F."'
Search Results
2. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling
3. Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
4. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial
5. Implementation of a Prediction Algorithm for Autologous and Allogeneic Collection for Hematopoietic Stem Cell Transplantation
6. TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment
7. Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease
8. Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab
9. The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)
10. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
11. Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials
12. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies
13. Allogeneic Transplantation for Unfavorable-Risk Acute Myeloid Leukemia
14. Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results
15. Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients
16. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure
17. Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting
18. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis
19. Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation
20. Hepatobiliary manifestations of acute myeloid leukemia
21. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
22. Severe Hypoalbuminemia at Day 90 Predicts Worse Nonrelapse Mortality and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
23. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
24. Allogeneic Hematopoietic Cell Transplantation for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors
25. Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia: A Comprehensive Review
26. Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)
27. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.